Anti-Rheumatic Drugs - Malta

Malta

The Anti-Rheumatic Drugs market in Malta is anticipated to witness a significant increase in revenue, projected to reach US$4.10m in 2024.
It is expected to exhibit a steady annual growth rate (CAGR 2024-2029) of 1.51%, leading to a market volume of US$4.42m by 2029.
In terms of global comparison, United States is projected to generate the highest revenue of US$34,700.00m in 2024.
Malta's demand for anti-rheumatic drugs is steadily increasing due to the aging population and rising prevalence of rheumatic diseases.

Key regions: Germany, United States, India, Japan, United Kingdom

Market

Region

Region comparison

Currency

Analyst Opinion

The Anti-Rheumatic Drugs market in Malta has been experiencing steady growth in recent years.

Customer preferences: Malta's population is aging, and as a result, there has been an increase in the number of cases of rheumatoid arthritis. This has led to an increase in demand for anti-rheumatic drugs in the country. Patients are looking for drugs that are effective in managing their symptoms while also being affordable.

Trends in the market: The Anti-Rheumatic Drugs market in Malta has been growing at a steady pace due to an increase in the number of cases of rheumatoid arthritis in the country. There has been a shift towards biologic drugs which are more effective in managing symptoms and have fewer side effects. However, these drugs are expensive and are not affordable for everyone. As a result, there has been an increase in the use of biosimilars, which are cheaper versions of biologic drugs.

Local special circumstances: Malta is a small country with a population of just under 500,000 people. The country has a well-developed healthcare system that provides universal healthcare to its citizens. The government heavily subsidizes the cost of drugs, which makes them affordable for patients. However, there are still concerns about the availability of drugs, especially in rural areas.

Underlying macroeconomic factors: Malta has a stable economy with a low unemployment rate. The country has a high standard of living and a well-developed healthcare system. The government heavily subsidizes the cost of drugs, which makes them affordable for patients. However, the cost of healthcare is increasing, and there are concerns about the sustainability of the healthcare system in the long run. The government is investing in new technologies and treatments to improve the quality of healthcare in the country.

Methodology

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.